Healthcare Industry News:  CryoLife 

Devices Personnel

 News Release - October 30, 2007

CryoLife Announces Additions to Management Team

ATLANTA, Oct. 30 (HSMN NewsFeed) -- CryoLife, Inc. (NYSE: CRY ), a biomaterials, medical device and tissue processing company, announced today that Scott B. Capps has been named vice president, clinical research, effective October 29, 2007. Mr. Capps has served as vice president and general manager of CryoLife Europa, Ltd., based in the U.K., since February 2005.

Mr. Capps joined CryoLife in 1995 and has held several positions with the Company including project director for heart valves, director of clinical research and director of European clinical affairs. He is a graduate of the Georgia Institute of Technology and holds a Master's degree in bioengineering from Clemson University.

In a related move, David N. Hollinworth, Ph.D., has joined the company as vice president and general manager of CryoLife Europa, Ltd., effective October 29, 2007. Previously, Dr. Hollinworth held various management positions including chief executive officer of Chameleon Biosurfaces, European cardiology marketing manager of Siemens Medical and European market development manager in cardiology at Medtronic. Dr. Hollinworth holds a Ph.D. in biochemistry from The University of Bristol and an M.B.A. from the London Business School.

"Scott did a terrific job for CryoLife Europa, and we are very excited about tapping into the expertise he gained while there. His experiences with CryoLife, both in Europe and stateside, make him well qualified to lead our clinical operations here," said Steven G. Anderson, president and CEO of CryoLife, Inc. "I am also very pleased to welcome Dr. Hollinworth as general manager of CryoLife Europa. His extensive background in the marketing of new technologies and products will be of great assistance in the introduction of our new product pipeline in the years ahead."

About CryoLife, Inc.

Founded in 1984, CryoLife, Inc. is a leader in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries throughout the United States and Canada. The Company's BioGlueŽ Surgical Adhesive is FDA approved as an adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in the European Community and approved in Canada and Australia for use in soft tissue repair. The Company also distributes the CryoLife-O'BrienŽ stentless porcine heart valve, which is CE marked for distribution within the European Community.


Source: CryoLife

Issuer of this News Release is solely responsible for its content.
Please address inquiries directly to the issuing company.



FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.